Drugs

HTA ID	Drug	Brand	Indication	Assessment status	Date
-	Prucalopride	Resolor®	For the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.	Rapid Review Complete	29th March 2011
24006	Quizartinib	Vanflyta®	Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia that is FLT3-ITD positive.	Rapid Review Complete	11th March 2024
-	Radium-223	Xofigo®	For the treatment of adults with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.  It is for use in the hospital setting.	Assessment Process Complete	12th December 2014
-	Ramucirumab	Cyramza®	In combination with paclitaxel for the treatment of adult patients with advanced GC or gastro oesophageal junction (GEJ) adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy and as monotherapy for the treatment of adult patients with advanced GC or GEJ adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.	Assessment Process Complete	26th July 2016
-	Ranolazine	Ranexa®	Cost-effectiveness of Ranolazine (Ranexa®)	Rapid Review Complete	19th November 2009
19054	Ravulizumab	Ultomiris®	For the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity and in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.	Assessment Process Complete	30th May 2022
20036	Ravulizumab	Ultomiris®	Indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve, or have received eculizumab for at least 3 months and have evidence of response to eculizumab.	Assessment Process Complete	28th July 2022
-	Recombinant Human Parathyroid Hormone	Natpar®	Is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.	Rapid Review Complete	21st May 2018
-	Regadenoson	Rapiscan®	Cost-effectiveness of Regadenoson (Rapiscan®)	Rapid Review Complete	2nd November 2011
21065	Regdanvimab	RegkironaTM	For the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.	Rapid Review Complete	10th January 2022
-	Regorafenib	Stivarga®	For the treatment of patients with gastrointestinal stromal tumours (GIST) who have been previously treated with two tyrosine kinase inhibitors and have progressed or are intolerant to prior treatment with two TKI’s.	Rapid Review Complete	6th October 2014
-	Regorafenib	Stivarga®	For the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.	Assessment Process Complete	1st July 2014
23017	Relugolix	Orgovyx®	Indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.	Rapid Review Complete	14th March 2024
21055	Relugolix with estradiol and norethisterone acetate	Ryeqo®	Is indicated for moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Rapid Review Complete	3rd February 2022
-	Reslizumab	Cinqaero®	Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Rapid Review Complete	1st March 2017
-	Retigabine	Trobalt®	Cost-effectiveness of Retigabine (Trobalt®)	Rapid Review Complete	6th April 2011
24007	Rezafungin	Rezzayo®	Rezafungin (Rezzayo®) is indicated for the treatment of invasive candidiasis in adults.	Rapid Review Complete	26th March 2024
-	Ribociclib	Kisqali®	In combination with an aromatase inhibitor (AI) is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy.	Assessment Process Complete	13th August 2018
-	Ribociclib	Kisqali®	Is indicated in combination with an aromatase inhibitor or fulvestrant for the treatment of pre-, peri- and post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine therapy, or in women who have received prior endocrine therapy:	Rapid Review Complete	11th July 2019
-	Rifaximin	Targaxan®	Is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age.	Rapid Review Complete	7th August 2013
-	Rilpivirine	Edurant®	In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive adult patients with a viral load ≤ 100,000 HIV-1 RNA copies/ml.	Rapid Review Complete	6th January 2012
-	Rilpivirine (R), emtricitabine (F), tenofovir alafenamide (TAF)	Odefsey®	For the treatment of adults and adolescents (≥ 12 years, body weight ≥35 kg) infected with HIV 1 without known mutations associated with resistance to the NNRTI class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/ml.	Rapid Review Complete	13th July 2016
22051	Rimegepant	Vydura®	For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.	NCPE Assessment Process Complete	18th May 2023
-	Rimonabant	Acomplia®	For the management of multiple cardiovascular risks in overweight or obese patients in Ireland	Assessment Process Complete	16th October 2006
-	Riociguat	Adempas®	For the treatment of Pulmonary arterial hypertension (PAH) and Chronic thromboembolic pulmonary hypertension (CTEPH).	Rapid Review Complete	20th May 2014
23061	Risankizumab	Skyrizi®	Risankizumab is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. The Applicant is seeking reimbursement in a subgroup of the licensed population, as second-line treatment after failure of the first biologic therapy.	NCPE Assessment Process Complete	7th November 2023
22038	Risankizumab	Skyrizi®	Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).	Rapid Review Complete	30th June 2022
19010	Risankizumab	Skyrizi®	Is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Assessment Process Complete	12th August 2021
21006	Risdiplam	Evrysdi™	For the treatment of 5q spinal muscular atrophy (SMA) in patients 2 months of age and older, with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.	NCPE Assessment Process Complete	20th October 2023
23071	Ritlecitinib	Litfulo®	For the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.	Rapid Review Complete	22nd December 2023
-	Rituximab	MabThera®	Is indicated in adults for Non-Hodgkin’s lymphoma (NHL): Is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy: As maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy: For the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.	Rapid Review Complete	24th September 2014
-	Rivaroxaban	Xarelto®	Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.	Rapid Review Complete	22nd November 2017
-	Rivaroxaban	Xarelto®	For the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.	Assessment Process Complete	18th June 2019
-	Rivaroxaban	Xarelto®	For the prevention of stroke in atrial fibrillation.	Assessment Process Complete	19th June 2012
-	Rivaroxaban	Xarelto®	For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement.	Full HTA Assessment	18th September 2008
-	Rivaroxaban	Xarelto®	For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.	Assessment Process Complete	24th February 2012
-	Rivaroxaban	Xarelto®	Rivaroxaban 10mg daily for the prevention of recurrent venous thromboembolism in patients who have completed at least 6 months anticoagulation therapy for DVT or PE.	Rapid Review Complete	22nd November 2017
-	Roflumilast	Daxas®	For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.	Full HTA Assessment	3rd November 2010
-	Rolapitant	Varuby®	For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.	Rapid Review Complete	13th June 2017
-	Romiplostim	Nplate®	Is indicated for chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Rapid Review Complete	19th July 2019
-	Romiplostim	Nplate®	Is indicated for the treatment of adult chronic ITP splenectomised patients who have had either an inadequate response or who are intolerant of corticosteroids and immunoglobulins and also as second line treatment for adult ITP non-splenectomised patients where surgery is contraindicated.	Rapid Review Complete	27th May 2015
21016	Romosozumab	Evenity®	For the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.	NCPE Assessment Process Complete	7th March 2023
23004	Ropeginterferon alfa-2b	Besremi®	Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.	NCPE assessment ongoing	3rd January 2024
-	Ropivacaine Readyfusor®	Ropivacaine Readyfusor®	For acute, postoperative pain management in adults. Readyfusor is used to maintain a continuous peripheral nerve block (CPNB) via a continuous infusion.	Rapid Review Complete	13th December 2018
21037	Roxadustat	Evrenzo™	For the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease.	Rapid Review Complete	6th October 2021
-	Ruxolitinib	Jakavi®	For the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.	Assessment Process Complete	9th July 2013
20008	Ruxolitinib	Jakavi®	For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.	Assessment Process Complete	21st July 2021
22007	Sacituzumab govitecan	Trodelvy®	Is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease.	NCPE Assessment Process Complete	24th March 2023
23079	Sacituzumab govitecan	Trodelvy®	Sacituzumab govitecan is indicated for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.	Rapid Review Complete	26th January 2024
-	Sacubitril/valsartan	Entresto®	For the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.	Assessment Process Complete	8th July 2016